CTI BioPharma to Report Second Quarter 2021 Financial Results on August 5, 2021

SEATTLE, July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) CTIC today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 6891246. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

About CTI BioPharma Corp.

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. We are headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts:

Argot Partners

+212-600-1902

cti@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-report-second-quarter-2021-financial-results-on-august-5-2021-301344010.html

SOURCE CTI BioPharma Corp.